Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 18/20 | 0.74 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 0.74 |
| ▸ | PLK2 | Q9NYY3 | 5/20 | 0.74 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.73 |
| ▸ | CLK2 | P49760 | 3/20 | 0.73 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.73 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.73 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.73 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.73 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.73 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.73 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.73 |
| ▸ | PRKCG | P05129 | 2/20 | 0.73 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.73 |
| ▸ | NEK4 | P51957 | 2/20 | 0.73 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.73 |
| ▸ | BRD4 | O60885 | 7/20 | 0.69 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.69 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.69 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72323 | 1.00 | PLK1 (0.74) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL72299 | 0.93 | PLK1 (0.65) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL72298 | 0.93 | PLK1 (0.65) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL1064354 | 0.88 | PLK1 (0.74) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL1064351 | 0.88 | PLK1 (0.74) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL1066176 | 0.87 | PLK1 (0.75) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL1066172 | 0.87 | PLK1 (0.75) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL73871 | 0.86 | PLK1 (0.91) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL73872 | 0.86 | PLK1 (0.91) | PLK1PLK3PLK2PRKD3CLK2 | |
| SCHEMBL6124279 | 0.86 | PLK1 (0.82) | PLK1PLK3PLK2PRKD3CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557818-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHAMACEUTICALS INCORPORATED (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557818-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHAMACEUTICALS INCORPORATED (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120122879-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122879-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122879-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-17 | — | — | US | disclosed |
| US-8129387-B2 | Substituted 5,6-dihydroimidazo[1,5-F]pteridines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129387-B2 | Substituted 5,6-dihydroimidazo[1,5-F]pteridines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129387-B2 | Substituted 5,6-dihydroimidazo[1,5-F]pteridines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2102210-B1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-02-09 | — | — | EP | disclosed |
| EP-2102210-B1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20100099686-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2010-04-22 | — | — | US | disclosed |
| US-20100099686-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2010-04-22 | — | — | US | disclosed |
| US-20100099686-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2010-04-22 | — | — | US | disclosed |
| WO-2008076392-A2 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122879-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K1 | PLK1 33/4885PLK3 373/4885PLK2 108/4885 |
| US-20100099686-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K1 | PLK1 33/4885PLK3 373/4885PLK2 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.